Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 38, 116117
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 38 references indexed in Scilit:
- Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020)Expert Opinion on Therapeutic Patents, 2020
- Inhibitors of Xanthine Oxidase: Scaffold Diversity and Structure‐Based Drug DesignChemMedChem, 2019
- New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety AlertArthritis & Rheumatology, 2018
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutNew England Journal of Medicine, 2018
- Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various DiseasesMedicinal Research Reviews, 2017
- Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicityEuropean Journal of Medicinal Chemistry, 2017
- GoutThe Lancet, 2016
- Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double‐blind, placebo‐controlled studyJournal of Clinical Pharmacy and Therapeutics, 2016
- Gout therapeutics: new drugs for an old diseaseThe Lancet, 2011
- FYX-051: A Novel and Potent Hybrid-Type Inhibitor of Xanthine OxidoreductaseThe Journal of Pharmacology and Experimental Therapeutics, 2011